Skip to main content
Equibles
IRD logo

IRD · Opus Genetics, Inc. · Investor Relations

Track IRD — free

Use IRD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.27 +0.34 (+8.65%) At close · Nov 4
Russell 2000 member Rebalance outlook locked
Market Cap
$326.96M
Shares
83.20M
Volume · Nov 4 1.16M Avg daily vol (3M) 2.48M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-15 Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
2026-09-09 Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
2026-08-06 Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
2026-06-16 Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
2026-05-12 Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
2026-04-07 Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
2026-03-10 Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
2026-01-08 Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
2025-11-12 Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
2025-11-06 FINAL FOR GLOBENEWSWIRE
2025-11-06 FINAL FOR GLOBENEWSWIRE

Past events

Date Event Type
2026-10-20 Chardan Annual Healthcare Conference Conference
2026-10-14 Retina in Rio Event
2026-10-04 Euretina 2026 Event
2026-10-04 EURETINA Congress Event
2026-10-01 Euretina 2026 Event
2026-09-09 OPGx-BEST1 Cohort 1 Data Conference Call Conference
2026-09-09 Investor Conference Call and Webcast Conference
2026-06-16 Opus Genetics Virtual R&D Science Forum Event
2026-06-03 2026 Jefferies Global Healthcare Conference Conference
2026-05-19 RBC Capital Markets 2026 Global Healthcare Conference Conference
2026-04-20 2026 Annual Meeting of Stockholders Shareholder meeting
2026-03-25 RBC Capital Markets Global Ophthalmology Conference Conference
2026-03-11 Citizens Life Sciences Conference Conference
2026-03-10 Leerink Global Healthcare Conference Conference
2025-10-21 Chardan's 9th Annual Genetic Medicines Conference Conference
2025-10-16 Eyecelerator @ American Academy of Ophthalmology (AAO) Event
2025-09-30 Opus Genetics LCA5 Data Conference Call Conference

Source: https://ir.opusgtx.com/

Key facts CIK 1228627 CUSIP 67577R102 13F (30d) 23 filings 23 filers Visit website Investor relations